D
Regeneron Pharmaceuticals, Inc. REGN
$542.52 -$7.48-1.36% NASDAQ
Recommendation
Prev Close
$550.00
Volume
1,307,806
Avg Vol (90D)
1,237,118
Market Cap
$58.12B
Dividend & Yield
$1.76(0.32%)
52-Week Range
$476.49 - $1,211.20
P/E (TTM)
14.00
EPS (TTM)
$39.29
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
5/15/2025 - MarketBeat
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
7/18/2025 - Zacks Investment Research
Bailard Inc. Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/18/2025 - Ticker Report
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bailard Inc.
7/18/2025 - MarketBeat
Wealthfront Advisers LLC Sells 1,173 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/18/2025 - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Whittier Trust Co.
7/18/2025 - Ticker Report
How Is The Market Feeling About Regeneron Pharmaceuticals?
7/17/2025 - Benzinga
Regeneron's Promising Study on Odronextamab for B-cell Non-Hodgkin Lymphoma
7/17/2025 - TipRanks Financial Blog
Regeneron's Promising Obesity Treatment Study: A Potential Game-Changer?
7/17/2025 - TipRanks Financial Blog
Cullen Frost Bankers Inc. Has $4.36 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/17/2025 - MarketBeat
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
7/16/2025 - CNBC: Healthcare
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating
7/16/2025 - Insider Monkey
Regeneron Advances Melanoma Treatment with New Phase 2 Trial
7/16/2025 - TipRanks Financial Blog
Regeneron's Latest Study on Gastrointestinal Blood Loss: Key Insights for Investors
7/16/2025 - TipRanks Financial Blog
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
7/16/2025 - Zacks Investment Research
Signaturefd LLC Buys 113 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/16/2025 - Ticker Report
23andMe Holding (MEHCQ, $4.85) entered Downtrend as Momentum indicator drops below 0 level on Jul 15, 2025
7/16/2025 - Tickeron - Stocks
Regeneron and Sanofi's Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis Treatment
7/15/2025 - TipRanks Financial Blog
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sumitomo Life Insurance Co.
7/15/2025 - Ticker Report
CenterBook Partners LP Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/15/2025 - Ticker Report
CenterBook Partners LP Sells 10,270 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/15/2025 - MarketBeat
Concord Asset Management LLC VA Has $1.33 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/15/2025 - MarketBeat
Leo Wealth LLC Has $748,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/15/2025 - MarketBeat
Ballentine Partners LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/15/2025 - Ticker Report
Best Biotech Stocks to Buy in 2025
5/13/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$14.09B
EBITDA (TTM)
$4.46B
EBIT (TTM)
$3.96B
Net Income (TTM)
$4.50B
Balance Sheet
Total Assets (Q)
$37.55B
Total Debt (Q)
$2.70B
Total Liabilities (Q)
$8.16B
Book Value Per Share (Q)
$277.50
Cash Flow
Cash from Operations (TTM)
$3.95B
Cash from Investing (TTM)
-$133.50M
Cash from Financing (TTM)
-$3.34B
Net Change in Cash (TTM)
$483.20M
Filings
Filing Date
Tuesday, April 29, 2025
Period Date
Monday, March 31, 2025
Next Filing
Beginning of August (est)
Price History
Loading...
Beta
0.55
7-Day Total Return
-1.82%
30-Day Total Return
11.88%
60-Day Total Return
-7.20%
90-Day Total Return
-27.05%
Year to Date Total Return
-23.93%
1-Year Total Return
-49.02%
2-Year Total Return
-25.12%
3-Year Total Return
-7.27%
5-Year Total Return
-17.35%
52-week Low
Jun 05, 2025 - $476.49
52-week High
Aug 27, 2024 - $1,211.20
Valuation
Market Cap
$58.12B - Large Cap
Enterprise Value
$43.20B
Price/Sales (TTM)
4.34
Price/Book (Q)
1.98
Dividends and Shares
Shares Outstanding
111.20
Dividend Per Share (Most Recent)
$0.88
Dividend Per Share (TTM)
$1.76
Corporate Info
Website
www.regeneron.com
Phone Number
914 847 7000
Address
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Country
United States
Year Founded
1988
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to... more
NASDAQ 07/18/2025 4:00PM Eastern Quotes delayed